225Ac-PSMA-617 targeted alpha therapy after Docetaxel based chemotherapy in the patients of metastatic castration resistant prostate cancer

Conclusions: 225Ac-PSMA-617 is a safe and tolerable treatment option for mCRPC that demonstrates marked anti-tumor activity with improvement in quality of life even in patients of metastatic CRPC who have been previously treated with taxane based chemotherapy. Significant improvement in survival and quality of life be achieved even in patients with residual disease which otherwise have very limited options. Further studies in clinical trial settings are essential for further assessing the effects of this very encouraging modality.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: SEN, I., Pant, V., Thakral, P., Raina, V., DAS, S., Sharma, K., MANDA, D. Tags: GU - Radioligand Therapy (Poster Session) Source Type: research